Indication

Hematologic malignancy

A hematologic malignancy is a broad clinical category encompassing cancers that originate in blood-forming tissues, such as the bone marrow, or in cells of the immune and lymphatic systems. Read more about Hematologic malignancy

5 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Hematologic malignancy therapies.

Showing 1–5 of 5 drugs

Filter & compare in the drug finder →Opens the drug finder with Hematologic malignancy preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Hematologic malignancy.

A hematologic malignancy is a broad clinical category encompassing cancers that originate in blood-forming tissues, such as the bone marrow, or in cells of the immune and lymphatic systems.

These neoplasms affect pediatric and adult populations and primarily include leukemias, lymphomas, and plasma cell neoplasms such as multiple myeloma, as well as related conditions like myelodysplastic syndromes and myeloproliferative neoplasms.

Pathophysiologically, they are characterized by the clonal expansion, impaired differentiation, and uncontrolled proliferation of abnormal hematopoietic or lymphoid precursors.

Clinically, this marrow infiltration and tissue disruption often result in cytopenias, impaired immune function, generalized lymphadenopathy, organomegaly, and systemic symptoms.

Personalize your experience

Follow Hematologic malignancy and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it